O’Melveny Advises SciNeuro in US$53 Million Equity Financing Led by LAV and ARCH Venture Partners

"O’Melveny advised SciNeuro in a US$53 million equity financing led by LAV and ARCH Venture Partners, with participation from new and existing investors. The proceeds will fund advancement of SciNeuro’s clinical‑stage pipeline targeting Lp-PLA21, beta amyloid and LRRK22 and continued discovery of therapies for other CNS disorders."

O’Melveny represented SciNeuro in its US$53 million equity financing, which was led by LAV and ARCH Venture Partners and included participation from new and existing investors. The financing will provide proceeds to advance SciNeuro Pharmaceuticals’ clinical‑stage pipeline. SciNeuro is a biotechnology company focused on developing therapies for neurodegenerative diseases. The funds will support the development of investigational programs targeting Lp-PLA21, beta amyloid and LRRK22, and will underwrite ongoing discovery efforts for additional central nervous system disorders. O’Melveny represented client(s) SciNeuro with a team composed by: partners Wenting Yu and Kurt Berney, and legal consultant Chris Wu.

O’Melveny Advises SciNeuro in US$53 Million Equity Financing Led by LAV and ARCH Venture Partners

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads